Galapagos Delivers Candidate Drug in GSK Alliance
Complete the form below to unlock access to ALL audio articles.
Galapagos will now start scale-up chemistry and comprehensive safety evaluation to initiate Phase I clinical trials in early 2012.
This latest pre-clinical candidate is a small molecule that meets the chemical and biological criteria set by GSK for a potential new medicine. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials in early 2012.
"The arthritis alliance with GSK has been very fruitful in delivering promising candidate drugs," said Onno van de Stolpe, CEO of Galapagos. "In this alliance, we currently have two clinical trials, with plans to progress this new candidate into the clinic next year."
